Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

Gilead Sciences (NASDAQ:GILD) had its price objective raised by stock analysts at Cantor Fitzgerald from $129.00 to $135.00 in a research report issued to clients and investors on Thursday,MarketScreener reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 15.21% from the stock’s current price. Cantor Fitzgerald also issued estimates for Gilead Sciences’ FY2025 earnings at $8.18 EPS and FY2026 earnings at $8.75 EPS.

GILD has been the subject of several other reports. Citigroup increased their price objective on Gilead Sciences from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Wednesday. Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a research note on Tuesday, August 19th. UBS Group upped their target price on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Finally, Rothschild & Co Redburn upped their target price on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research note on Friday, September 12th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $118.08.

Gilead Sciences Stock Up 0.4%

GILD opened at $117.18 on Thursday. Gilead Sciences has a 1-year low of $84.17 and a 1-year high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $145.40 billion, a price-to-earnings ratio of 23.34, a P/E/G ratio of 0.79 and a beta of 0.34. The business has a 50 day moving average of $114.65 and a 200-day moving average of $110.25.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same period in the prior year, the business earned $2.01 earnings per share. Gilead Sciences’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, sell-side analysts anticipate that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the completion of the transaction, the chief executive officer directly owned 605,725 shares in the company, valued at $69,016,306.50. This represents a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the transaction, the chief financial officer owned 159,555 shares of the company’s stock, valued at $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 82,000 shares of company stock valued at $9,402,130. 0.27% of the stock is owned by insiders.

Institutional Trading of Gilead Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. CHICAGO TRUST Co NA increased its stake in shares of Gilead Sciences by 95.0% in the third quarter. CHICAGO TRUST Co NA now owns 5,654 shares of the biopharmaceutical company’s stock valued at $628,000 after buying an additional 2,754 shares in the last quarter. Arlington Financial Advisors LLC increased its stake in shares of Gilead Sciences by 1.7% in the third quarter. Arlington Financial Advisors LLC now owns 44,734 shares of the biopharmaceutical company’s stock valued at $4,965,000 after buying an additional 747 shares in the last quarter. Thomasville National Bank increased its stake in shares of Gilead Sciences by 1.7% in the third quarter. Thomasville National Bank now owns 107,245 shares of the biopharmaceutical company’s stock valued at $11,904,000 after buying an additional 1,750 shares in the last quarter. Flputnam Investment Management Co. increased its stake in shares of Gilead Sciences by 5.6% in the third quarter. Flputnam Investment Management Co. now owns 63,497 shares of the biopharmaceutical company’s stock valued at $7,048,000 after buying an additional 3,395 shares in the last quarter. Finally, Quotient Wealth Partners LLC increased its stake in shares of Gilead Sciences by 13.3% in the third quarter. Quotient Wealth Partners LLC now owns 9,120 shares of the biopharmaceutical company’s stock valued at $1,012,000 after buying an additional 1,073 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.